Skip to main content
SpringerLink
Log in

Human Papillomavirus (HPV)

  • Chapter
  • First Online:
The Clinician’s Vaccine Safety Resource Guide

Abstract

All males and females without contraindications ages 11-12 years should receive two doses of HPV vaccine administered 6-12 months apart. Vaccination can be started as young as 9 years of age. Those who start the series after the age of 15 should receive three doses of HPV vaccine, with the second and third doses administered 1-2 months and 6 months after the first dose, respectively. If not previously vaccinated, catch-up vaccination is recommended for all males through age 21 and females through age 26. Males ages 22-26 years may also be vaccinated. If doses are delayed there is no need to repeat doses since increasing the interval between doses is generally associated with enhanced immune responses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    A serious adverse event is defined by the Food and Drug Administration (FDA) as resulting “in any of the following outcomes: Death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.” This definition is found in Title 21, §312.32 of the Electronic Code of Federal Regulations, which can be accessed at the following link: http://www.ecfr.gov/cgi-bin/text-idx?SID=6b68426ec6d55c78a6799d161ba6754c&mc=true&node= se21.5.312_132&rgn=div8

References

  1. Epidemiology and Prevention of Vaccine-Preventable Diseases, Hamborsky J, Kroger A, Wolfe S, eds. 2015, Centers for Disease Control and Prevention: Washington D.C.

    Google Scholar 

  2. Meites, E., A. Kempe, and L.E. Markowitz, Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep, 2016. 65(49): p. 1405–8.

    Article  Google Scholar 

  3. Markowitz, L.E., et al., Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2014. 63(Rr-05): p. 1–30.

    PubMed  Google Scholar 

  4. Petrosky, E., et al., Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep, 2015. 64(11): p. 300–4.

    PubMed  PubMed Central  Google Scholar 

  5. Kroger, A.T., J. Duchin, and M. Vázquez. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). 2017 [cited 2017 October]; Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.

  6. Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep, 2008. 57(17): p. 457–60.

    Google Scholar 

  7. Braun, M.M., P.A. Patriarca, and S.S. Ellenberg, Syncope after immunization. Arch Pediatr Adolesc Med, 1997. 151(3): p. 255–9.

    Article  CAS  Google Scholar 

  8. Bernard, D.M., et al., The domino effect: adolescent girls’ response to human papillomavirus vaccination. Med J Aust, 2011. 194(6): p. 297–300.

    PubMed  Google Scholar 

  9. Bednarczyk, R.A., et al., Sexual Activity–Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds. Pediatrics, 2012.

    Google Scholar 

  10. Naleway, A.L., et al., Primary Ovarian Insufficiency and Adolescent Vaccination. Pediatrics, 2018.

    Google Scholar 

  11. Lipkind, H.S., et al., Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol, 2017. 130(3): p. 599–608.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Epidemiologist, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Matthew Z. Dudley PhD, MSPH

  2. Professor, Departments of International Health and Health, Behavior and Society, Director, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Daniel A. Salmon PhD, MPH

  3. Professor Emeritus, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Professor Emeritus, Department of Pediatrics, Johns Hopkins School of Medicine, Director Emeritus, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Neal A. Halsey MD

  4. Professor of Medicine, Pediatrics, Global Health, and Epidemiology, Emory University, Associate Director, Emory Vaccine Center, Director, Center of Excellence for Influenza Research and Surveillance (Emory-UGA CEIRS), Former President, National Foundation for Infectious Diseases (NFID), Atlanta, GA, USA

    Walter A. Orenstein MD, DSc (Hon)

  5. Associate Director for Behavioral Research, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Rupali J. Limaye PhD, MPH, MA

  6. Associate Professor, Pediatrics-Infectious Diseases, University of Colorado School of Medicine, Denver, CO, USA

    Sean T. O’Leary MD, MPH

  7. William H. Foege Professor of Global Health, Professor of Epidemiology and Pediatrics, Emory University, Atlanta, GA, USA

    Saad B. Omer MBBS, PhD, MPH

Authors
  1. Matthew Z. Dudley PhD, MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. Salmon PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neal A. Halsey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter A. Orenstein MD, DSc (Hon)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rupali J. Limaye PhD, MPH, MA
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sean T. O’Leary MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Saad B. Omer MBBS, PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dudley, M.Z. et al. (2018). Human Papillomavirus (HPV). In: The Clinician’s Vaccine Safety Resource Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-94694-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-94694-8_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-94693-1

  • Online ISBN: 978-3-319-94694-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation